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Abstract
BACKGROUND & AIMS—Serotonin (5-hydroxytryptamine [5-HT]) has an important role in 
gastrointestinal function. LX1031 is an oral, locally acting, small molecule inhibitor of tryptophan 
hydroxylase (TPH). Local inhibition of TPH in the gastrointestinal tract might reduce mucosal 
production of serotonin (5-HT) and be used to treat patients with nonconstipating irritable bowel 
syndrome (IBS).
METHODS—We evaluated 2 dose levels of LX1031 (250 mg or 1000 mg, given 4 times/day) in a 
28-day, multicenter, randomized, double-blind, placebo-controlled study of 155 patients with 
nonconstipating IBS. 5-hydroxyindoleacetic acid (5-HIAA), a biomarker of pharmacodynamic 
activity, was measured in urine samples at baseline (24 hours after LX1031 administration), and at 
weeks 4 and 6 (n = 76).
RESULTS—Each dose of LX1031 was safe and well-tolerated. The primary efficacy end point, 
relief of IBS pain and discomfort, improved significantly in patients given 1000 mg LX1031 
(25.5%), compared with those given placebo, at week 1 (P = .018); with nonsignificant 
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improvements at weeks 2, 3, and 4 (17.9%, 16.3%, and 11.6%, respectively). Symptom 
improvement correlated with a dose-dependent reduction in 5-HIAA, a marker for TPH inhibition, 
from baseline until week 4. This suggests the efficacy of LX1031 is related to the extent of 
inhibition of 5-HT biosynthesis. Stool consistency significantly improved, compared with the 
group given placebo, at weeks 1 and 4 (P < .01) and at week 2 (P < .001).
CONCLUSIONS—In a phase 2 study, LX1031 was well tolerated, relieving symptoms and 
increasing stool consistency in patients with nonconstipating IBS. Symptom relief was associated 
with reduced levels of 5-HIAA in urine samples. This marker might be used to identify patients 
with nonconstipating IBS who respond to inhibitors of 5-HT synthesis.
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Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder that currently 
is not fully understood or adequately treated.1,2 The negative impact of IBS on quality of life 
is severe; moreover, IBS is associated with direct and indirect medical costs that are 
surprisingly large.3–6 IBS is defined as a symptom complex, which means that a clinical 
diagnosis of IBS may identify a population of patients with a heterogeneous underlying 
pathophysiology.7 The Rome III criteria were developed to standardize the diagnostic 
criteria for IBS and emphasize altered bowel habits with recurrent pain and/or discomfort.8 
IBS may be associated predominantly with diarrhea (IBS-D), constipation, or a mixed 
pattern of each.9,10
Gastrointestinal (GI) serotonin (5-hydroxytryptamine [5-HT]) may play an important role in 
the pathophysiology of nonconstipating IBS.2,11,12 Although 5-HT also is produced by 
neurons in the brain and in the pineal gland,13 the GI tract contains, by far, the largest depot 
of 5-HT in the body.14 This 5-HT is found both in mucosal enterochromaffin (EC) cells15 
and in myenteric interneurons.11,16,17 The biosynthesis of 5-HT occurs in 2 steps: a rate-
limiting enzyme, tryptophan hydroxylase (TPH), first converts L-tryptophan to 5-
hydroxytryptophan, which then is converted to 5-HT by aromatic L-amino acid 
decarboxylase18 (Figure 1).
There are 2 isoforms of TPH, which are the products of separate genes, TPH1 and TPH2. 
TPH1 is found in EC cells, mast cells, and pinealocytes,19–21 whereas TPH2 is restricted to 
central and enteric neurons.16,22,23 The TPH1-dependent 5-HT of EC cells is released in 
response to a variety of signals, including increased intraluminal pressure and acid, which 
initiate peristaltic and secretory reflexes.24–27 Release of 5-HT from EC cells activates the 
mucosal projections of intrinsic primary afferent neurons, which in turn activate the 
microcircuits responsible for secretory as well as peristaltic reflexes.28–33 5-HT also 
stimulates extrinsic primary afferent neurons to convey noxious signals, including pain and 
nausea, to the central nervous system.34–38 Within the enteric nervous system, TPH2-
dependent 5-HT is a neurotransmitter that mediates excitatory pathways regulating motility 
and secretion.11,12,39
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Reports of gene polymorphisms abnormalities in EC cell number, 5-HT secretion, TPH1, 
serotonin transporter, and 5-HT receptors in subsets of patients with IBS suggest that 
abnormalities of 5-HT production, secretion, or action within the gut may have a role in the 
disordered motility and the discomfort characteristic of IBS.40–49 Drugs such as 
alosetron50,51 and cilansetron,52 which target 5-HT3 receptors, have been found to be 
effective in the treatment of IBS-D, whereas those that target 5-HT4 receptors are effective 
in the treatment of IBS-C.53–57 Although these compounds are not in wide use because of 
safety concerns,58 clinical benefit associated with treatment supports the concept that drugs 
that modify actions of 5-HT provide symptomatic relief for at least a subset of IBS patients. 
Given that 5-HT signaling is associated with increased GI activity, we developed LX1031, a 
locally acting inhibitor of TPH and 5-HT biosynthesis as a potential new therapy for 
nonconstipating IBS.59 This phase 2 study was designed to test the hypothesis that treatment 
with LX1031 would produce clinical improvements in symptoms of nonconstipating IBS 
and these improvements would be associated with a reduction in mucosal 5-HT production.
Materials and Methods
Study Design
This phase 2 clinical trial was conducted as a multicenter, randomized, double-blind, 
placebo-controlled, proof-of-concept study. Male and female patients 18 to 70 years of age 
with an established history of nonconstipating IBS (IBS-D and mixed-subtype IBS) based 
on ROME III criteria were recruited across 36 centers in the United States. Diagnostic 
criteria for nonconstipating IBS included symptom onset 6 months or more before study 
enrollment, with presence of abdominal pain or discomfort in the 3 months before 
enrollment. All patients were required to have a normal colonoscopy. In addition, patients 
were required to have no history of alarm signs or symptoms including fever, GI bleeding, 
weight loss, anemia, or abdominal mass. With the exception of bulking agents, medications 
used in the management of nonconstipating IBS symptoms (eg, antidiarrheal agents such as 
loperamide, diphenoxylate, bismuth subsalicylate, paregoric and anticholinergic 
antidepressants, opioid analgesic drugs, or other drugs that specifically affect bowel motility 
[prescription, over-the-counter, or herbal]), were to be discontinued 30 days before 
enrollment. There were no dietary restrictions during the study period. Patients who had 
received any investigational agent within 3 months of the start of the study also were 
excluded. The institutional review board at each participating center approved the research 
and all patients who participated in the study provided written informed consent. This study 
was registered with ClinicalTrials.gov (NCT00813098).
The clinical trial consisted of 4 study periods: screening, a 14-day run-in, a 28-day 
treatment, and a 14-day follow-up. During run-in, patients were required to complete daily 
diary records (10 of 14 days) to establish the extent of their baseline symptoms. Patients 
meeting the appropriate inclusion criteria were assigned randomly in a double-blind fashion 
to 1 of 2 doses of LX1031 (250 mg 4 times/day or 1000 mg 4 times/day) or placebo, taken 
daily during the 28-day treatment period; randomization was conducted centrally in blocks 
of 3. Separate written informed consent was obtained from patients willing to participate in 
evaluation of biomarkers directly associated with LX1031 mechanism of action: 24-hour 
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urinary 5-hydroxyindoleacetic acid (5-HIAA) and whole-blood 5-HT. Urinary 5-HIAA 
samples were obtained at baseline and week 4 of the treatment period, and at the 2-week 
follow-up visit. Three samples of whole blood for assessment of 5-HT were obtained on the 
same days, with 1 sample being obtained while the patient was fasting and 2 samples 
postprandially, at 0.5 and 2.0 hours after a standardized, carbohydrate-rich meal.
Study Outcomes
Study outcomes were evaluated through the use of daily reporting into an interactive voice 
response system (IVRS), and visual analog scales (VAS). The prespecified primary efficacy 
end point was impact on global subjective assessment of pain and discomfort across the 4-
week study treatment period (adequate relief assessment) based on a weekly response to the 
question, “In the past 7 days, have you had adequate relief of your IBS pain and 
discomfort?” In addition, secondary efficacy end point assessments included the following: 
IBS global assessment of improvement scale (7-point scale), urgency to defecate, Bristol 
Stool Form Scale (7-point scale), stool frequency, abdominal pain (4-point scale and VAS), 
and bloating (4-point scale and VAS).
Safety was evaluated weekly through a symptom-oriented physical examination, vital signs, 
review of concomitant medication(s), adverse event (AE) reports, hematology, and blood 
chemistry. In addition, electrocardiograms (ECGs) were obtained at baseline, at week 4 of 
the treatment period, and at completion of the week 2 follow-up period.
Statistical Analysis
Sample size calculations and power ranking equivalents were modeled using estimates of 
response rates, variability of study assessments, and differences between treatment and 
placebo arms with various placebo response rates. Based on simulated trial modeling 
estimates, in the presence of a 20% treatment difference, the probability of observing a 
greater than 0.05 difference (response rate to active drug minus response rate to placebo) 
approximated 90% with 45–50 subjects per arm.
Data were analyzed using descriptive summaries of the absolute and change from baseline 
for mean scores by week. The change from baseline in mean scores for each week was fitted 
using an analysis of covariance model, with baseline as the covariate. The safety analysis 
was conducted using the safety population, comprised of all patients who received at least 1 
dose (or any portion thereof) of study drug or placebo; a predefined, per-protocol population 
was used in the analysis of efficacy variables. This population was required to be 80% or 
more compliant with the study medication, answer 75% or more of the IVRS questions 
concerning global subjective relief, and complete the study. Biochemical variables were 
summarized by measures of central tendency and the corresponding measures of variance. 
Relationships between biochemical markers and efficacy end points were evaluated using 
logistic regression models.
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Between December 2008 and September 2009 a total of 227 patients were screened for 
inclusion in the protocol; 155 met enrollment criteria and were randomized to study 
medication. Of these, 142 completed the study with 134 meeting the predefined 
requirements for inclusion in the per-protocol population (Figure 2). All sites were given the 
opportunity to participate in the biomarker substudy; 76 patients at 19 of 34 sites 
participated. Patients enrolled in the biomarker substudy were demographically 
representative of the total patient population. The baseline characteristics of the 155 patients 
randomly assigned to the study groups are summarized in Table 1. Demographic variables 
between treatment and placebo groups were well balanced.
Efficacy Outcomes
Evaluating the prespecified primary efficacy end point of global subjective adequate relief 
outcome, a statistically significant improvement of 25.5% was observed in the high-dose 
(HD) LX1031 group over placebo at week 1 (47.5% vs 22.0%; P = .018) with nonsignificant 
improvements of 17.9%, 16.3%, and 11.6% over placebo observed for weeks 2, 3, and 4, 
respectively (Figure 3A, and Table 2). Over time, patients receiving the placebo showed an 
improved response, reaching levels similar to that seen in the low-dose (LD) LX1031 arm. 
Stool consistency, a secondary end point measured by the Bristol Stool Form Scale, 
improved in the HD arm at weeks 1, 2, and 4 vs placebo (P < .01 weeks 1 and 4, P < .001 
week 2) (Figure 3B, Table 2). In an effort to determine whether patients experienced a 
benefit as compared with placebo over the entire 4-week treatment period as a whole, a 
nonprespecified analysis of area under the curve was conducted that revealed that the HD 
group experienced a significant improvement (P = .047) in adequate relief from 
nonconstipating IBS pain and discomfort. After discontinuation of therapy, improvement 
observed in both adequate relief and stool consistency based on the daily Bristol Stool Form 
Scale disappeared rapidly, such that by 1 week after drug discontinuation, values were 
similar across both dose groups and placebo. There were no significant differences between 
the treatment groups and the placebo group for the other prespecified secondary efficacy 
variables at any time during the study.
For patients who consented to participate in the biomarker substudy, a statistically 
significant relationship in the HD group was observed between the percentage decrease of 
urinary 5-HIAA and the improvement in the global subjective adequate relief from baseline 
to week 4 (P = .027, using the Wald statistic from logistic regression) (Figure 4A). Overall, a 
25% change in median urinary 5-HIAA was observed after 4 weeks of treatment between 
the HD and placebo groups. A more modest reduction occurred in the LD group and 
minimal changes were seen in the placebo group (Table 2). No significant changes in whole-
blood 5-HT were observed, which may be attributed to the limited turnover of platelets, a 
reservoir of 5-HT, during the 4-week treatment period.
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Relationship of Clinical Improvement to Biochemical Markers of TPH Inhibition
To explore the potential use of the biomarker to distinguish those patients most responsive to 
LX1031 treatment, a retrospective analysis of those individuals who participated in the 
urinary 5-HIAA biomarker substudy was performed. Because the LD and placebo groups 
were not significantly distinguished with respect to the primary end point by week 4, treated 
patients were stratified based on urinary 5-HIAA: less than 15% reduction or 15% or greater 
reduction (a level that distinguished the HD group from both the placebo and LD groups). 
For the 24 individuals randomly assigned to HD LX1031 who participated in the substudy, 
15 (63%) achieved a 15% or greater reduction in urinary 5-HIAA (5-HIAA biomarker 
responders), compared with 9 patients (37%) with a 5-HIAA reduction of less than 15% (5-
HIAA biomarker nonresponders). Notably, 73% of patients in the HD 5-HIAA biomarker 
responder group reported achieving adequate relief of nonconstipating IBS pain and 
discomfort at week 4, whereas only 11% of the HD 5-HIAA biomarker nonresponders did 
so (P = .011; Figure 4B). The HD 5-HIAA biomarker responder group also experienced 
significantly greater improvements in stool consistency than did those in the HD group who 
did not reduce their 5-HIAA to a similar extent (Figure 4C).
Although there were no significant differences in the secondary efficacy assessments in the 
per-protocol population, the HD 5-HIAA biomarker responder group showed improvement 
in global measures and a number of additional GI symptoms (Figure 4D). By using the IBS 
global assessment of improvement 7-point scale, an overall subjective symptom 
improvement was observed compared with baseline (P = .026), whereas no differences had 
been observed in the per-protocol population with this instrument.
Adverse Effects
AEs reported were generally mild, self-limited, and evenly distributed across the placebo 
and both LX1031 treatment arms. In addition, there was no evidence of a dose response with 
respect to AEs. Thirteen patients discontinued therapy over the 4-week treatment period. Of 
these, 7 discontinued because of an AE (placebo, n = 1; 250 mg 4 times/day, n = 4; and 1000 
mg 4 times/day, n = 2), including: insomnia, urinary tract infection, supraventricular 
tachycardia (pre-existing condition), gagging at pill ingestion, worsening of nonconstipating 
IBS symptoms, rash, and the only serious AE that was reported (transient ischemic attack 
unrelated to study drug). The remaining 6 discontinuations were due to the following: lost to 
follow-up evaluation (n = 1), withdrawn consent (n = 2), lack of compliance (n = 1), 
withdrawn by the principal investigator (n = 1), or inability to complete study procedures (n 
= 1). There were no clinically significant abnormalities observed in laboratory parameters, 
ECGs, or physical examinations. The most frequent AEs affected the GI system, as might be 
expected within this patient population (Table 3). Among the 5 patients with diarrhea in the 
HD group, most events were mild to moderate, fewer than 3 days in duration, and resolved 
without additional intervention. In addition, there was no temporal relationship to initiation 
of study drug dosing with the occurrence of these events. None of the patients who 
experienced events of diarrhea participated in the biomarker substudy.
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LX1031 was developed as an oral TPH inhibitor that acts locally on the GI mucosa, gaining 
access primarily to TPH in the intestinal lining and thereby inhibiting 5-HT synthesis in the 
GI epithelium. The favorable safety profile observed in this study may be related, in part, to 
its local site of action in the GI tract, ability to inhibit 5-HT synthesis at the level of the EC 
cell, and low degree of oral bioavailability and systemic exposure. This exploratory phase 2 
study shows that LX1031 may be effective in improving symptoms in patients with 
nonconstipating IBS with a significant number of patients reporting that they had 
experienced adequate symptom relief during the first week of therapy. Significant 
improvements also were observed in stool consistency at weeks 1, 2, and 4. These 
observations support the concept that nonconstipating IBS symptoms may be improved by 
inhibiting TPH.
Biomarker findings from this study are consistent with the idea that mucosal 5-HT 
dysregulation may influence nonconstipating IBS symptoms in a subset of patients. Indeed, 
the use of LX1031 also provides a pharmacologic probe that can further our understanding 
of the etiology of nonconstipating IBS by allowing the relationship between the change in a 
biomarker that reflects 5-HT biosynthesis (urinary 5-HIAA) and symptoms to be examined. 
The 5-HIAA biomarker also supports the linkage of clinical efficacy to the mechanism of 
action of LX1031: inhibition of TPH and reduction of serotonin synthesis. LX1031 has been 
shown consistently to reduce mucosal 5-HT production in preclinical models,59 in a phase 1 
study of normal volunteers,60 and now in a phase 2 study of nonconstipating IBS patients.
Because EC cells contain the bulk of the 5-HT in the body, urinary measurements of 5-
HIAA largely reflect the metabolism of GI mucosal 5-HT. If 5-HT release from EC cells or 
5-HT hypersensitivity were to contribute to the etiology of nonconstipating IBS, then 
LX1031 would be expected to provide symptom relief to those patients who respond 
biochemically to LX1031, as shown by a decrease in urinary 5-HIAA. Conversely, patients 
who do not have a decrease in urinary 5-HIAA would be unlikely to show clinical 
improvement in response to therapy. The observation in this study, that relief of symptoms 
was associated with a decrease in urinary 5-HIAA, is consistent with these predictions.
The investigation of new drugs for the treatment of nonconstipating IBS is challenging 
because of a combination of factors including the heterogeneity of the patient population and 
variability in both subjective assessments and pharmacologic response. As such, there are 
inevitable and recognized limitations specific to the current study: (1) limited baseline 
disease severity data and IBS treatment history, (2) variability associated with treatment of 
patients with both mixed-subtype IBS and IBS-D; (3) limited sample size, duration of 
treatment, and follow-up periods, and (4) a high placebo effect (although not atypical for 
such trials).
Certain dimensions of nonconstipating IBS drug development and patient management 
could be improved through access to an objective biomarker that correlates with clinical 
response and pharmacologic action. The retrospective observation in this study that patients 
manifesting a reduction in urinary 5-HIAA excretion of 15% or more showed improvement 
Brown et al. Page 7













in multiple efficacy parameters (Figure 4C) suggests that it may be possible to prospectively 
identify patients who are most likely to benefit from therapies designed to reduce serotonin 
synthesis in the GI tract. For example, it may be possible to use the biochemical response to 
LX1031, as measured by the reduction of urinary 5-HIAA over an initial dosing period, to 
identify those patients who are most likely to benefit from longer-term treatment. Therapy 
also could be individualized with respect to dose, based on the level of biomarker response 
to initial treatment followed by dose titration until a desired pharmacologic threshold effect 
is achieved in order to maximize the potential for clinical benefit. Although significant 
variability was observed in the biomarker parameters in this study, which in part may relate 
to differences in diet for foods rich in tryptophan, a dose-dependent effect was observed in 
the reduction of 24-hour urinary 5-HIAA. The lack of response to the compound in some 
patients may be due to increased GI transit time (limiting drug access to EC cells) or other 
factors limiting effective exposure of the compound to the epithelial surface of the GI tract. 
For such patients, a response might be obtained at higher doses of LX1031, or with an 
alternative compound or formulation with improved access to the mucosal epithelium.
Conclusions
LX1031, a locally acting TPH inhibitor, appeared safe and well tolerated in this exploratory 
phase 2 study over 4 weeks in patients with symptomatic, nonconstipating IBS. Results 
suggest that reduction of mucosally derived 5-HT may positively influence symptoms 
common to nonconstipating IBS. Importantly, a relationship was observed between 
improvement in symptoms and a reduction in 24-hour urinary 5-HIAA, a biomarker that 
corresponds to the rate of 5-HT synthesis and the mechanism of action of LX1031. The use 
of this biomarker may allow for identification of the subset of patients who have the best 
chance of experiencing an improvement in their nonconstipating IBS symptoms through 
therapy with a TPH inhibitor. Further studies with TPH inhibitors will be required to 
confirm these initial clinical findings and the related hypothesis that reduction of GI mucosal 
5-HT correlates with symptom improvement in patients with nonconstipating IBS.
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Biosynthetic pathway of 5-HT production.
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Study disposition. QID, 4 times/day.
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(A) Percentage of patients experiencing adequate relief on a weekly basis. (B) Weekly mean 
scores of daily Bristol Stool Form Scale (range, 1–7; 1–2 for constipation; 6–7 for diarrhea). 
ΔAUC, change in area under the curve; QID, 4 times/day.
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(A) Relationship between improvement in adequate relief and decline in 24-hour urinary 5-
HIAA. (B) HD urinary 5-HIAA biomarker responders vs nonresponders achieving adequate 
relief on a weekly basis. (C) HD urinary 5-HIAA biomarker responders vs nonresponders 
Bristol Stool Form scale effects. (D) HD urinary 5-HIAA biomarker responders vs 
nonresponders across all efficacy outcomes. QID, 4 times/day.
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Table 1
Baseline Characteristics of the Study Population
Variable Placebo (n = 52) LX1031 250 mg QID (n = 54) LX1031 1000 mg QID (n = 49)
Mean age ± SD, y 48.0 ± 12.43 47.5 ± 12.93 48.7 ± 11.96
Sex, n (%)
  Male 8 (15.4) 8 (14.8) 9 (18.4)
  Female 44 (84.6) 46 (85.2) 40 (81.6)
Race, n (%)
  White 47 (90.4) 49 (90.7) 43 (87.8)
  Black 2 (3.8) 4 (7.4) 6 (12.2)
  Asian 1 (1.9) 0 (0) 0 (0)
  Other 2 (3.8) 1 (1.9) 0 (0)
IBS type, n (%)
  IBS-D 37 (71.2) 42 (77.8) 39 (79.6)
  Mixed-type IBS 15 (28.8) 12 (22.2) 10 (20.4)
(n = 47) (n = 44) (n = 43)a
Mean disease severity scores
  Bloat VAS 49.16 45.58 48.15
  Bloat 4-point scale 1.82 1.67 1.74
  Pain VAS 50.21 47.62 47.42
  Pain 4-point scale 1.84 1.78 1.73
  Frequency 2.92 3.35 3.3
  Urgency 0.79 0.82 0.84
  Stool Form VAS 4.24 4.09 4.26
QID, 4 times/day; VAS, visual analog scale.
a
n = 42 for bloat VAS and pain VAS.
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Table 2
Efficacy End Points
Adequate relief of IBS pain and discomfort, % Placebo (n = 47) LX1031 250 mg QID (n = 44) LX1031 1000 mg QID (n = 43)
Patients achieving adequate relief (primary
    efficacy end point), %
  Treatment week 1 22.0 37.5 47.5a
  Treatment week 2 31.1 33.3 51.2
  Treatment week 3 42.6 37.2 53.5
  Treatment week 4 42.6 41.9 53.5
  Follow-up week 1 26.8 40.5 32.5
  Follow-up week 2 25.8 26.7 30.3
Weekly mean scores of Daily Bristol Stool
    Form scale (±SD)
  Baseline 4.24 (±1.05) 4.09 (±0.99) 4.26 (±1.039)
  Treatment week 1 3.89 (±1.006) 3.70 (±1.010) 3.37b (±1.257)
  Treatment week 2 3.74 (±0.972) 3.86 (±1.005) 3.14b (±1.338)
  Treatment week 3 3.57 (±1.114) 3.83 (±0.916) 3.27 (±1.211)
  Treatment week 4 3.64 (±1.118) 3.79 (±0.915) 3.14b (±1.04)
  Follow-up week 1 3.98 (±1.232) 4.12 (±0.837) 3.86 (±1.170)
  Follow-up week 2 3.85 (±1.185) 3.75 (±1.061) 3.65 (±1.098)
Biochemical evaluation of efficacy
(n = 21) (n = 29) (n = 26)
Median 24-hour urinary 5-HIAA (mg/24 h)
  Baseline 3.35 3.20 2.80
  Treatment week 4 3.20 2.65 2.10
  Follow-up week 2 3.40 3.15 2.40
  Change (baseline vs week 4) −4.48% −17.19% −25.00%
QID, 4 times/day; SD, standard deviation.
a
P ≤ .05 vs placebo.
b
P ≤ .01 vs placebo.
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Table 3
Adverse Events
Preferred term Placebo (n = 52) n (%) LX1031 250 mg QID (n = 54) n (%) LX1031 1000 mg QID (n = 49) n (%)
Nausea 4 (7.7) 5 (9.3) 4 (8.2)
Diarrhea 2 (3.8) 1 (1.9) 5 (10.2)
Dyspepsia 2 (3.8) 3 (5.6) 0
Vomiting 0 2 (3.7) 2 (4.1)
Headache 2 (3.8) 3 (5.6) 3 (6.1)
Somnolence 1 (1.9) 2 (3.7) 1 (2.0)
Dizziness 0 2 (3.7) 0
Dysgeusia 0 2 (3.7) 0
Urinary tract infection 1 (1.9) 0 2 (4.1)
Blood amylase level increased 0 2 (3.7) 0
White blood cell increased 0 2 (3.7) 0
Back pain 2 (3.8) 0 2 (4.1)
NOTE. AEs occurring in more than 1 patient at a rate greater than placebo by preferred term.
QID, 4 times/day
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